Federal Circuit affirms Latuda decision in Sumitomo clash

The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Sumitomo sues over antipsychotic drug

14 February 2018 Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

Americas

Federal Circuit dismisses attorneys’ fees appeal

12 June 2018 An Indiana district court did not abuse its discretion in denying attorneys’ fees to medical device company Cook Medical, the US Court of Appeals for the Federal Circuit said yesterday in a precedential decision.

Big Pharma

Japanese firm acquires US drugmaker after increasing offer

25 October 2022 The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.

More on this story

Americas

Sumitomo sues over antipsychotic drug

14 February 2018 Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

Americas

Federal Circuit dismisses attorneys’ fees appeal

Big Pharma

Japanese firm acquires US drugmaker after increasing offer

25 October 2022 The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.

More on this story

Americas

Sumitomo sues over antipsychotic drug

14 February 2018 Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

Americas

Federal Circuit dismisses attorneys’ fees appeal

Big Pharma

Japanese firm acquires US drugmaker after increasing offer

25 October 2022 The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.